RNL Bio, opens its second stem cell clinic in Yanji, China

Nov. 13, 2008 - PRLog -- RNL Bio, a biopharmaceutical company dedicated to development of adult stem cell therapeutics, announced today that it opened RNL ChoYang Center for Stem Cell and Regenerative Medicine (RNL CSCRM) in Yanji, China.

The celebration was attended by Yanji government officials, the Director of Yanji health authority and officials from RNL Bio. All of them spoke about the importance of establishing a hospital which is specialized in state-of-the-art stem cell therapeutics, utilizing the most innovative medical technologies.

RNL CSCRM, plans to offer stem cell therapeutics to treat degenerative diseases relating to the aging process.  These therapies would assist reversal of the aging process by promoting cellular reparation and regeneration.  Future plans include the establishment of an internal institute of stem cell research to manufacture and supply stem cells directly to the hospital.

RNL Bio’s stem cell therapies are autologous and derived from one’s own fat tissue thus does not have any harmful side effects.  The cells are then administered into patients by both local injection and/or intravenous infusion. IV infusion of patients’ own stem cells has advantages of a simple and less invasive delivery of stem cells for treatment.  Indications include most cell damaging diseases which include, liver cirrhosis, renal failure, osteoarthritis, brain infarction, Alzheimer’s and Parkinson’s diseases.

RNL CSMRM expects to see positive results using stem cell therapeutics derived from autologous adipose tissue derived stem cells.  Unlike Korea and the U.S., China’s regulatory authority approves the physician’s administration of autologous stem cell therapy via ex-vivo expansion.  RNL plans to use its stem cell therapeutics that are already in clinical trials (in Korea) in China as well.

After RNL opened its first stem cell clinic in Beijing, China, RNL CSRM is the second hospital of RNL to open in China. RNL plans to expand its hospital network by establishing stem cell hospitals in up to 100 regions in China including Shanghai, Hong Kong, Qingdao and Macao.

Dr. Jeong-Chan Ra, president and CEO of RNL Bio, said “Through the Yanji clinic, RNL will acquire an abundance of clinical experience on the stem cell treatment of various disease resulting from cellular damage” “In Korea, there is high demand for stem cell therapeutics. We plan to offer medical tour services and expect it to be very popular in the near future.”

Contact to RNL Bio(+82-2874-0686 ext 107)

# # #

RNL is a premier biotech company in Korea focused on stem cell therapeutics. Headquartered in Seoul with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190)